
-
Blueprint Medicines Corporation NasdaqGS:BPMC Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Location: 45 Sidney Street, Cambridge, MA, 02139, United States | Website: https://www.blueprintmedicines.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
6.682B
Cash
576.2M
Avg Qtr Burn
-36.39M
Short % of Float
9.44%
Insider Ownership
0.87%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AYVAKIT® (avapritinib) Details Systemic Mastocytosis | Approved Quarterly sales | |
AYVAKIT (avapritinib) Details PDGFRA mutant GIST (Gastrointestinal Stromal Tumors) | Approved Quarterly sales | |
GAVRETO (parlsetinib) Details Non-small cell lung carcinoma, Thyroid cancer, Cancer, Solid tumor/s | Approved Quarterly sales | |
BLU-808 Details Chronic urticaria, CSU/CInDu, allergic rhinitis/allergic conjunctivitis | Phase 2 Initiation | |
BLU-945 +/- osimertinib Details Cancer, Solid tumor/s, Non-small cell lung carcinoma | Phase 1/2 Update | |
BLU-451 Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Phase 1/2 Update | |
BLU-222 (CDK12) Details Breast cancer, Cancer | Phase 1/2 Update | |
Elenestinib Details Systemic Mastocytosis | Phase 1 Update |